NCT05847790

Brief Summary

The goal of this clinical trial is to determine the effectiveness of remote nonstress test (NST) compared to in-clinic NSTs in improving fetal testing completion rates. Participants will be randomized to either in-clinic NSTs or use of an FDA-approved remote monitoring belt for their pregnancy monitoring.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 27, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

May 8, 2023

Completed
17 days until next milestone

Study Start

First participant enrolled

May 25, 2023

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 26, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 26, 2025

Completed
Last Updated

October 30, 2025

Status Verified

May 1, 2025

Enrollment Period

2.3 years

First QC Date

April 27, 2023

Last Update Submit

October 28, 2025

Conditions

Keywords

Fetal monitoringantenatal testing

Outcome Measures

Primary Outcomes (2)

  • Overall Fetal Testing Completion Rate

    percentage of recommended antenatal testing sessions that were successfully completed as defined as a clinically interpreted test was performed

    from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

  • Fetal Testing Completion Rate in Black versus non-Black subjects

    Comparison between Black and non-Black subjects' percentage of recommended antenatal testing sessions that were successfully completed as defined as a clinically interpreted test was performed.

    from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

Secondary Outcomes (24)

  • Fetal Monitoring outcomes: Number of visits to the antenatal testing unit

    from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

  • Fetal Monitoring outcomes: Frequency of provider recommended prolonged monitoring

    from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

  • Fetal Monitoring outcomes: Time on NST monitor

    from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

  • Fetal Monitoring outcomes: Number of non-reactive NSTs

    from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

  • Fetal Monitoring outcomes: Number of biophysical profiles performed for non-reactive NST tests

    from 32 weeks gestational age to delivery, average of 10 weeks after enrollment.

  • +19 more secondary outcomes

Study Arms (2)

Remote NST

EXPERIMENTAL
Device: Invu monitoring belt

In-clinic NST - Standard of Care

ACTIVE COMPARATOR
Other: Standard of care

Interventions

INVU monitoring belt used for remote NSTs

Remote NST

In-clinic NSTs - standard of care

In-clinic NST - Standard of Care

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Singleton pregnancy
  • Gestational age between 30 weeks 0 days and 35 weeks 6 days
  • Pregnant patients who have clinical indication for fetal surveillance with NSTs (based on UPHS Health System clinical guidelines for antenatal monitoring)
  • Able to provide written consent
  • English speaking

You may not qualify if:

  • Multiple gestations
  • Maternal pre-gravid BMI greater than 45kg/m2
  • Presence of an implanted pacemaker or defibrillator
  • Active abdominal skin infection
  • A known amniotic fluid index (AFI) less than 5cm or greater than 25cm on the most recent ultrasound (if available) prior to randomization
  • Delivery is planned within 2 weeks of potential randomization

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

MeSH Terms

Interventions

Standard of Care

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of OBGYN

Study Record Dates

First Submitted

April 27, 2023

First Posted

May 8, 2023

Study Start

May 25, 2023

Primary Completion

September 26, 2025

Study Completion

September 26, 2025

Last Updated

October 30, 2025

Record last verified: 2025-05

Locations